Genetic Determinants of P2Y12 Inhibitors and Clinical Implications

Interventional Cardiology Clinics

Volumn 6, Issue 1, 2017, Pages 141-149

  Cavallari, Larisa H ^a   Obeng, Aniwaa Owusu ^b,c  

^a UNIVERSITY OF FLORIDA   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c MOUNT SINAI HOSPITAL   (United States)

Author keywords

Clopidogrel; CYP2C19; Genotype; Pharmacogenomics; Prasugrel; Ticagrelor

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C19; PRASUGREL; PURINERGIC P2Y RECEPTOR ANTAGONIST; TICAGRELOR; CYP2C19 PROTEIN, HUMAN; TICLOPIDINE;

ACUTE CORONARY SYNDROME; CLINICAL OUTCOME; DRUG DOSE ESCALATION; DRUG EFFICACY; GENOTYPE; HUMAN; PERCUTANEOUS CORONARY INTERVENTION; PHARMACODYNAMICS; PHARMACOGENETICS; PHARMACOGENOMICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; ALLELE; ANALOGS AND DERIVATIVES; DRUG EFFECT; GENETICS; METABOLISM; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOSIS;

ACUTE CORONARY SYNDROME; ALLELES; CYTOCHROME P-450 CYP2C19; GENOTYPE; HUMANS; PERCUTANEOUS CORONARY INTERVENTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PURINERGIC P2Y RECEPTOR ANTAGONISTS; THROMBOSIS; TICLOPIDINE;

EID: 84997234930     PISSN: 22117458     EISSN: 22117466     Source Type: Journal    
DOI: 10.1016/j.iccl.2016.08.010     Document Type: Review

References (57)

1. 1 Sabatine, M.S., Cannon, C.P., Gibson, C.M., et al., Clopidogrel as Adjunctive Reperfusion Therapy -Thrombolysis in Myocardial Infarction I. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 294 (2005), 1224–1232.
2. 2 Mehta, S.R., Yusuf, S., Peters, R.J., et al., Clopidogrel in Unstable angina to prevent Recurrent Events trial I. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358 (2001), 527–533.
3. 3 Khalil, B.M., Shahin, M.H., Solayman, M., et al. Genetic and nongenetic factors affecting clopidogrel response in the Egyptian population. Clin Transl Sci 9 (2016), 23–28.
4. 4 Cuisset, T., Quilici, J., Grosdidier, C., et al. Comparison of platelet reactivity and clopidogrel response in patients 75 years undergoing percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome. Am J Cardiol 108 (2011), 1411–1416.
5. 5 Hochholzer, W., Trenk, D., Fromm, M.F., et al. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J Am Coll Cardiol 55 (2010), 2427–2434.
6. 6 Wiviott, S.D., Braunwald, E., McCabe, C.H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 (2007), 2001–2015.
7. 7 Wallentin, L., Becker, R.C., Budaj, A., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361 (2009), 1045–1057.
8. 8 Laine, M., Paganelli, F., Bonello, L., P2Y12-ADP receptor antagonists: days of future and past. World J Cardiol 8 (2016), 327–332.
9. 9 Kazui, M., Nishiya, Y., Ishizuka, T., et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 38 (2010), 92–99.
10. 10 Karazniewicz-Lada, M., Danielak, D., Burchardt, P., et al. Clinical pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases. Clin Pharmacokinet 53 (2014), 155–164.
11. 11 Gurbel, P.A., Bliden, K.P., Hiatt, B.L., et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107 (2003), 2908–2913.
12. 12 Jaremo, P., Lindahl, T.L., Fransson, S.G., et al. Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med 252 (2002), 233–238.
13. 13 Stone, G.W., Witzenbichler, B., Weisz, G., et al., ADAPT-DES Investigators. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 382 (2013), 614–623.
14. 14 Angiolillo, D.J., Bernardo, E., Sabate, M., et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 50 (2007), 1541–1547.
15. 15 Wiviott, S.D., Trenk, D., Frelinger, A.L., et al., PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in comparison to Clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial. Circulation 116 (2007), 2923–2932.
16. 16 Roe, M.T., Goodman, S.G., Ohman, E.M., et al. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel. Circulation 128 (2013), 823–833.
17. 17 Bonello, L., Pansieri, M., Mancini, J., et al. High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. J Am Coll Cardiol 58 (2011), 467–473.
18. 18 Gurbel, P.A., Bliden, K.P., Butler, K., et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 120 (2009), 2577–2585.
19. 19 Yousuf, O., Bhatt, D.L., The evolution of antiplatelet therapy in cardiovascular disease. Nat Rev Cardiol 8 (2011), 547–559.
20. 20 Htun, W.W., Steinhubl, S.R., Ticagrelor: the first novel reversible P2Y(12) inhibitor. Expert Opin Pharmacother 14 (2013), 237–245.
21. 21 Trenk, D., Hochholzer, W., Fromm, M.F., et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 51 (2008), 1925–1934.
22. 22 Mega, J.L., Close, S.L., Wiviott, S.D., et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 119 (2009), 2553–2560.
23. 23 Shuldiner, A.R., O'Connell, J.R., Bliden, K.P., et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302 (2009), 849–857.
24. 24 Sibbing, D., Stegherr, J., Latz, W., et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J 30 (2009), 916–922.
25. 25 Collet, J.P., Hulot, J.S., Pena, A., et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 373 (2009), 309–317.
26. 26 Hulot, J.S., Bura, A., Villard, E., et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108 (2006), 2244–2247.
27. 27 Scott, S.A., Sangkuhl, K., Shuldiner, A.R., et al. PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19. Pharmacogenet Genomics 22 (2012), 159–165.
28. 28 Jeong, Y.H., Bliden, K.P., Park, Y., et al. Pharmacogenetic guidance for antiplatelet treatment. Lancet, 380, 2012, 725 [author reply: 725–6].
29. 29 Scott, S.A., Sangkuhl, K., Stein, C.M., et al., Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther 94 (2013), 317–323.
30. 30 Sibbing, D., Gebhard, D., Koch, W., et al. Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy. J Thromb Haemost 8 (2010), 1685–1693.
31. 31 Tiroch, K.A., Sibbing, D., Koch, W., et al. Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events. Am Heart J 160 (2010), 506–512.
32. 32 Pare, G., Mehta, S.R., Yusuf, S., et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med 363 (2010), 1704–1714.
33. 33 Mega, J.L., Close, S.L., Wiviott, S.D., et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360 (2009), 354–362.
34. 34 Palmerini, T., Calabro, P., Piscione, F., et al. Impact of gene polymorphisms, platelet reactivity, and the SYNTAX score on 1-year clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention: the GEPRESS study. JACC Cardiovasc Interv 7 (2014), 1117–1127.
35. 35 Mega, J.L., Simon, T., Collet, J.P., et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 304 (2010), 1821–1830.
36. 36 Doll, J.A., Neely, M.L., Roe, M.T., et al., TRILOGY ACS Investigators. Impact of CYP2C19 metabolizer status on patients with ACS treated with prasugrel versus clopidogrel. J Am Coll Cardiol 67 (2016), 936–947.
37. 37 Holmes, M.V., Perel, P., Shah, T., et al. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA 306 (2011), 2704–2714.
38. 38 Sorich, M.J., Rowland, A., McKinnon, R.A., et al. CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel: a meta-analysis. Circ Cardiovasc Genet 7 (2014), 895–902.
39. 39 Mega, J.L., Close, S.L., Wiviott, S.D., et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet 376 (2010), 1312–1319.
40. 40 Lewis, J.P., Horenstein, R.B., Ryan, K., et al. The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response. Pharmacogenet Genomics 23 (2013), 1–8.
41. 41 Brandt, J.T., Close, S.L., Iturria, S.J., et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 5 (2007), 2429–2436.
42. 42 Harmsze, A., van Werkum, J.W., Bouman, H.J., et al. Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation. Pharmacogenet Genomics 20 (2010), 18–25.
43. 43 Malek, L.A., Kisiel, B., Spiewak, M., et al. Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel. Circ J 72 (2008), 1165–1169.
44. 44 Horenstein, R.B., Madabushi, R., Zineh, I., et al. Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers. J Clin Pharmacol 54 (2014), 865–873.
45. 45 Mega, J.L., Hochholzer, W., Frelinger, A.L. 3rd, et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA 306 (2011), 2221–2228.
46. 46 Carreras, E.T., Hochholzer, W., Frelinger, A.L., et al. Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel. Insights form the ELEVATE-TIMIT 56 Trial. Thromb Haemost 116 (2016), 69–77.
47. 47 Rehmel, J.L., Eckstein, J.A., Farid, N.A., et al. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab Dispos 34 (2006), 600–607.
48. 48 Wallentin, L., James, S., Storey, R.F., et al., PLATO investigators. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 376 (2010), 1320–1328.
49. 49 Sorich, M.J., Vitry, A., Ward, M.B., et al. Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data. J Thromb Haemost 8 (2010), 1678–1684.
50. 50 Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, Writing Committee Members, et al. ACCF/AHA Clopidogrel clinical alert: approaches to the FDA “boxed warning”: a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association. Circulation 122 (2010), 537–557.
51. 51 Peterson, J.F., Field, J.R., Unertl, K., et al. Physician response to implementation of genotype-tailored antiplatelet therapy. Clin Pharmacol Ther 100:1 (2016), 67–74.
52. 52 Shuldiner, A.R., Palmer, K., Pakyz, R.E., et al. Implementation of pharmacogenetics: the University of Maryland Personalized Anti-platelet Pharmacogenetics Program. Am J Med Genet C Semin Med Genet 166C (2014), 76–84.
53. 53 Weitzel, K.W., Elsey, A.R., Langaee, T.Y., et al. Clinical pharmacogenetics implementation: approaches, successes, and challenges. Am J Med Genet C Semin Med Genet 166C (2014), 56–67.
54. 54 Lee, J.A., Lee, C.R., Reed, B.N., et al. Implementation and evaluation of a CYP2C19 genotype-guided antiplatelet therapy algorithm in high-risk coronary artery disease patients. Pharmacogenomics 16 (2015), 303–313.
55. 55 Cavallari, L.H., Magvanjav, O., Anderson, R.D., et al. Clinical implementation of CYP2C19 genotype guided antiplatelet therapy reduces cardiovascular events after PCI. Circulation, 132, 2015, A11802.
56. 56 Franken, C.C., Kaiser, A.F., Kruger, J.C., et al. Cytochrome P450 2B6 and 2C9 genotype polymorphism–a possible cause of prasugrel low responsiveness. Thromb Haemost 110 (2013), 131–140.
57. 57 Varenhorst, C., Eriksson, N., Johansson, A., et al., PLATO Investigators. Effect of genetic variations on ticagrelor plasma levels and clinical outcomes. Eur Heart J 36 (2015), 1901–1912.